Genelex’s CEO Medicare Comments on Warfarin DNA Testing

Posted on September 3, 2008 by DNADiva

Today is the last day to express your opinion on whether warfarin (Coumadin) DNA testing should be covered by insurance. Please post your comments on this important decision which will have far reaching effects on the field of personalized medicine and pharmacogenetics. Please go to http://www.cms.hhs.gov/mcd/viewtrackingsheet.asp?from2=viewtrackingsheet.asp&id=224& to learn more about this study. To post your comments [...]

Filed under: Cytochrome P450, Personalized Medicine, Pharmacogenetics | Tagged: , , , , , , | 1 Comment »

Warfarin DNA Testing Reimbursement Public Comment DEADLINE Wednesday 9/3/08

Posted on August 27, 2008 by DNADiva

Here is a recent email sent by Genelex’s CEO, Howard Coleman to people with an interest in personalized medicine:    It’s time to express your opinion on whether warfarin (Coumadin) DNA testing should be paid for by insurance. The Center for Medicare and Medicaid Services (CMS) has initiated a study of this topic and is accepting [...]

Filed under: Cytochrome P450, Personalized Medicine, Pharmacogenetics | Tagged: , , , , , , | 2 Comments »

How Many Deaths Will it Take?

Posted on November 29, 2007 by DNADiva

I read an article recently by Dr. Mrazek at the Mayo Clinic entitled “How Many Deaths Will it Take.” The article pointed out the number of deaths from adverse drug reactions and that widespread adoption of pharmacogenetic testing would reduce this number. Yesterday, Dr. Mrazek’s statement came closer to home. I received an e-mail from Roman [...]

Filed under: Cytochrome P450, Personalized Medicine, Pharmacogenetics | Tagged: , , , , , , | 1 Comment »

Genetic Guidance of Warfarin Dosing Shows Promise from Heartwire – Sue Hughes

Posted on November 15, 2007 by DNADiva

November 7, 2007 (Orlando, FL) – Using genetic tests as well as clinical factors improved the accuracy and efficiency of warfarin dose initiation, but the primary end point of a reduction in out-of- range INRs was not significantly changed in the overall population in the Couma-Gen study [1]. Subgroup analysis suggested, however, that pharmacogenetic guidance [...]

Filed under: Cytochrome P450, Personalized Medicine, Pharmacogenetics | Tagged: , , , , , | 2 Comments »

Follow

Get every new post delivered to your Inbox.